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PENGESANAN DNA PORSIN TERHADAP FORMULASI TABLET AM DAN 
EKSIPIEN 
ABSTRAK 
 
 
 Permintaan pasaran ke atas produk farmaseutikal halal telah meningkat 
disebabkan oleh kesedaran pengguna Muslim terhadap produk halal. Dengan 
teknologi pengesahan DNA, eksipien dan produk akhir yang dicemari dengan 
kandungan porsin boleh dikesan dengan melakukan ujian kuantitatif tindak balas 
rantai polimerase (qPCR). Dalam kajian ini, tablet telah dipilih dan tiga jenis 
formulasi tablet telah dipilih; tidak bersalut, bersalut filem dan tablet pelepasan 
berterusan. Pengesanan DNA porsin telah dilakukan pada setiap eksipien digunakan 
dalam formulasi tiga jenis tablet. Templat kawalan positif dan negatif tablet tidak 
bersalut, tablet bersalut filem dan pelepasan berterusan tablet telah dihasilkan 
mengikut standard farmaseutikal untuk mengesan DNA porsin. Porsin dan bovin 
gelatin digunakan sebagai ejen pencemar dalam setiap eksipien dan sebagai pengikat 
dalam tablet kawalan positif dan negatif. Hasilnya, DNA porsin dikesan dalam 
semua eksipien yang dicemar dan tablet kawalan positif. Didapati bahawa larutan 
CTAB dapat memerangkap DNA dari matriks polisakarida yang terkandung dalam 
sodium starch glycolate dan prgelatinised starch. Keputusan menunjukkan bahawa 
kaolin yang terkandung dalam eksipiens salutan mempunyai tarikan yang tinggi 
kepada DNA dan dalam keadaan beralkali, interaksi yang kuat antara kaolin dan 
DNA boleh menjadi lemah. Hasil kajian menunjukkan bahawa porsin DNA masih 
boleh Berjaya diperoleh dan dikesan selepas proses pengeringan untuk pengeluaran 
tablet tidak bersalut. Oleh itu, pengesanan DNA porsin menggunakan kaedah ujian 
xix 
 
qPCR boleh digunakan untuk mengesan kandungan porsin dalam tablet dan eksipien, 
apabila teknik pengekstrakan tertentu digunakan. 
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PORCINE DNA DETECTION IN COMMON TABLET FORMULATIONS 
AND EXCIPIENTS 
 
ABSTRACT 
 
 
 Market demand on halal pharmaceutical products has increased due to the 
awareness of Muslim consumers towards halal products. With DNA verification 
technology, porcine content in adulterated excipients and final product can be 
detected by performing quantitative polymerase chain reaction (qPCR) test. In this 
study, tablet was chosen and three types of tablet formulation were selected; 
uncoated, film-coated and sustained-release tablets. Porcine DNA detection was 
assessed in each excipient used in formulating the three types of tablets. A template 
of positive and negative controls of uncoated tablet, film-coated tablet and sustained-
release tablet were developed according to pharmaceutical standard for porcine DNA 
detection. Porcine and bovine gelatines were used as a spiking agent in each 
excipient and as a binder in positive and negative controls tablets. As a result, 
porcine DNA was detected in all spiked excipients and positive control tablets. It was 
found that CTAB solution was able to entrap DNA from polysaccharide matrix 
contained in sodium starch glycolate and pregelatinised starch. The results indicated 
that kaolin contained in coating excipients has a high affinity to DNA and in alkaline 
condition, the tight interaction of kaolin and DNA can be weakened. The results 
showed that porcine DNA was still able to be retrieved and detected after the drying 
process for uncoated tablet production.  Thus, porcine DNA detection using qPCR 
testing method can be applied to detect porcine content in tablet and its excipients, 
when certain extraction techniques are adhered to. 
 1 
CHAPTER 1 : INTRODUCTION 
 
1.1 AWARENESS ON HALAL PRODUCT 
 
 Halal is a term that has its origins from the Arabic language. It is defined as 
things or actions that are permitted by the Shariah law (Law of Islam).  Haram is the 
opposite word for Halal, and it refers to actions or things that are prohibited for 
Muslims. A halal product can be defined as a product that is free from haram sources 
such as pork or porcine derivatives and is produced in a hygienic manner. A halal 
product can also be generally defined as safe, hygienic and of high quality (Aziz et 
al., 2012). In recent years, halal is not only being applied to food and beverage. These 
non-food halal products range from cosmetic, pharmaceutical, packaging to personal 
care. Beyond that, halal services are also emerging in recent years in the finance, 
insurance, tourism, entertainment, testing laboratory and logistic industries (Rahim et 
al., 2013). The awareness of non-Muslim consumer towards halal verification is 
increasing as halal products are known to be safer, of good quality and the animals 
are slaughtered in a less harmful way (Zainalabidin et al., 2010). In addition, the 
awareness of consumers towards halal product is not only limited to processed meat 
and food but they also start to seek halal pharmaceuticals and cosmetics, as shown in 
Figure 1.1 (Zain, 2011).    
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Figure 1.1 Percentage of awareness indicating the Malaysian consumers’ demand of 
halal requirements towards different products  (Zain, 2011) 
1.2 MARKET DEMAND ON HALAL PHARMACEUTICAL PRODUCTS 
 
 Currently, market demands on halal pharmaceutical products are 
tremendously increasing because the Muslim population is the second largest 
religious community in the world as shown in Figure 1.2 (CIA, 2013), and halal 
adherence in products has become increasingly sought out as it is a Muslim’s 
obligation to conform to the Holy Quran. According to Pew Research Centre (2009), 
Muslim population in the world will massively grow from 1.6 billion in 2010 to 2.8 
billion by 2050. As the Muslim population will grow exponentially within the 
upcoming years, it is expected that there will a positive growth in the halal market 
business. In addition, global halal market was projected to be worth US$580 billion a 
year (Aziz et al., 2012) and halal pharmaceutical products constitute a fragment of 
this growing market.  
 
96%
52%
27%
20%
Awareness on Halal Product
Processed meat
Processed food
Pharmaceutical
products
Cosmetic
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Figure 1.2 Percentage of world population based on religion. (CIA, 2013) 
In April 2011, Malaysia has established its own halal pharmaceutical standards – 
Malaysian Standards MS2424:2012 and it is the first in the world (Peng et al., 2012). 
Halal pharmaceutical standards are defined as pharmaceutical products that comply 
with good manufacturing practices (GMPs) and halal quality assurance. The standard 
is developed as a guideline to all pharmaceutical industries intending to produce a 
halal pharmaceutical product that is safe to be consumed and is hygienic.  
 
High market demand for halal pharmaceutical products and the establishment of 
halal pharmaceutical standards have led to the emergence of halal pharmaceutical 
and nutraceutical companies. Chemical Company of Malaysia Berhad (CCM) was 
the first pharmaceutical company in Malaysia that produced halal certified 
supplement products. Beside CCM, Safwa Health supplements also produced several 
halal certified supplement products that are manufactured in Australia. In Brunei, 
Simpor Pharma is the first pharmaceutical company to produced halal certified 
supplement products (Zaili, 2015).  
christian, 33.39%
muslim, 22.74%
hindu, 
13.80%
buddhist, 6.77%
sikh, 0.35%
jewish, 0.22%
baha'i, 0.11%
other religions, 
10.95%
non-religious, 
9.66%
atheists, 2.01%
Percentage of World Population based on Religions, 2012
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1.3 CURRENT HALAL VERIFICATION METHOD ON HALAL 
PHARMACEUTICAL PRODUCTS 
 
1.3.1 Consumer  
 
 Generally, a Muslim consumer verifies that a product, including health 
supplements, is halal by checking the authentic halal logo labelled on the packaging 
visually. Alternatively, a list of halal pharmaceutical products can be obtained from a 
local halal regulatory body portal such as Halal Malaysia Official Portal. Well-
informed Muslim consumers will check the source of active ingredient and 
excipients contained in the product. In certain cases, they would ask directly from the 
pharmaceutical company when there are animal-derived excipients contained in the 
product but no halal logo on the packaging. 
 
1.3.2 Halal regulatory body 
 A halal regulatory body is designated for halal certification and enforcement, 
and it verifies whether the processes and ingredients used comply with the Shariah 
law. Examples of halal regulatory bodies are the LPPOM MUI of Indonesia, 
Department of Islamic Development Malaysia (JAKIM), Islamic Food and Nutrition 
Council of America (IFANCA), Islamic Food and Nutrition Council of Canada 
(IFANCC) and Office of Muslim Affairs of the Philippines. 
 
The verification methods for pharmaceutical products used by JAKIM are done on-
site and paper audits. In certain situations, the regulatory body will send the product 
or evidence to halal testing laboratory when the product is suspected to be 
contaminated or adulterated with haram sources.  
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1.3.3 Researchers 
 To date, most published literatures regarding halal verification methodology 
are based on the presence of haram sources such as porcine and trace of alcohol. In 
recent years, researchers are focusing on porcine trace detection method in meat and 
processed food as well as alcohol level detection, due to the higher susceptibility of 
these products to be adulterated with porcine-derivative or high alcohol contents 
(Regenstein et al., 2003; Man et al., 2011; Senyuva et al., 2013). Halal verification 
on porcine trace detection in pharmaceutical products is still at its infancy.  
 
1.4 DNA AS TARGET TOOL FOR PORCINE TRACE DETECTION 
 In the analytical method for porcine trace detection, a target or marker is 
needed for quantitative and qualitative analysis. Currently, there are various targets 
used for porcine trace detection such as protein, fatty acid, RNA and DNA. Protein 
analysis is efficient for detection in unprocessed products (Zhang et al., 2007), fatty 
acid analysis is effective mainly for animal-derived fats (Lumley et al., 1996). RNA 
analysis is difficult compared to other analysis because it requires an RNAse-free 
technique in addition to RNA being an unstable molecule (Tan et al., 2009).  
DNA analysis is the most common target tool for porcine trace detection in 
processed products (Mafra et al., 2008) because DNA has proven to be able to 
withstand product processing better than other targets such as protein (Woolfe et al., 
2004). Compared to protein, DNA carries much more of the organism’s genetic 
information and it is a relatively stable molecule in the cell, allowing species 
identification in processed products (Hammes et al., 1995). The limitation of using 
DNA as a target, however, is the low quantity of DNA in processed product, and it 
can be damaged and degraded into small fragments due to exposure to harsh 
 6 
condition such as mechanical shearing. Fortunately, DNA is amplifiable through the 
polymerase chain reaction (PCR) process.   
1.4.1 DNA extraction and isolation method 
 In 1869, a Swiss physician, Friedrich Miescher was the first to perform DNA 
isolation from cells (Mischer, Miescher, 1869; Dahm et al., 2005). Current DNA 
extraction and isolation method has been further optimized to obtain a purified DNA 
in an effective way (Tan et al., 2009).  
 
DNA extraction and isolation method is also known as nucleic acid extraction. There 
are two types of nucleic acid extraction, which are conventional method and solid-
phase extraction. One of the examples for conventional method is 
cetyltrimethylammonium bromide (CTAB) extraction method. This method is 
usually applied to extract DNA from plant sample, in which CTAB, a cationic 
surfactant will precipitate the polysaccharide matrix contained in the plant extract 
(Sambrook et al., 2001). Commercial DNA purification kits available in the market 
commonly applied solid-phase nucleic acid extraction because this extraction method 
is efficient in purification of DNA, and it is less time-consuming compared to the 
conventional method (Esser et al., 2005). The extraction is efficient because less 
amount of sample is needed and the application of rapid centrifugation and column 
separation during the extraction steps make the duration of nucleic acid purification 
process faster  (Gjerse et al., 2009). Silica matrices, glass particles, and magnetic 
bead-based nucleic acid purification are several examples of solid-phase nucleic acid 
extraction. Silica matrix is the most basic matrix used for nucleic acid purification. 
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Generally, a combination of conventional method and solid phase extraction is 
necessary to maximise the amount of extracted DNA from a sample that contains 
matrices or contaminants especially samples from processed products. When 
contaminants or matrices are present in extracted DNA, it will become an inhibitor 
and disrupt the process of DNA quantification and detection. Proteinase K, an 
enzyme that digests protein also plays an important role during DNA extraction in 
processed product that is heterogeneous. This enzyme cleaves the peptide bond in 
proteins and works optimally at 65°C. A purified DNA sample will indicate that the 
DNA extraction and isolation method has been carried out efficiently.  
 
1.4.2 Quantitative polymerase chain reaction (qPCR) testing method for porcine   
 DNA detection 
 In 1983, Kary Bank Mullis together with Michael Smith invented the PCR 
technique, and they were later awarded with a Nobel prize (Mullis et al., 1987). PCR 
works by enzymatically replicating a small amount of extracted DNA and amplifying 
it repeatedly in several cycles to produce multiple copies of DNA (Saiki et al., 1988).  
 
The first instrument used for DNA amplification was a thermal cycler, which became 
commercially available in 1987.  In recent years, quantitative PCR (qPCR) is one of 
the latest instruments used for DNA detection. qPCR testing is a sensitive and 
effective method to detect specific DNA fragment which is available only in a small 
quantity. Hence, qPCR is commonly used for DNA detection in forensic samples and 
GMO products (Alonso et al., 2004).  In porcine DNA detection, qPCR is also 
commonly used to identify porcine trace in meat, processed food and gelatine. qPCR 
can monitor the output of DNA amplification with fluorescence marker (McCartney 
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et al., 2003). At certain PCR cycle, the fluorescence signal will start to emit, showing 
the presence of targeted DNA. Cycle threshold (Ct) value is used to measure the 
amplified DNA. A low Ct value would indicate a high amount of DNA template 
present in the extracted DNA sample.  
 
As mentioned earlier, qPCR testing method is based on the detection of fluorescence 
signal emitted during PCR cycle.  The source of fluorescence signal can be divided 
into two categories.  The first category applies DNA-intercalating agents such as 
SYBRGreen I and EvaGreen (Navarro, 2014). DNA-intercalating agent is the 
simplest signal agent, but it detects both specific and non-specific DNA target. On 
the other hand, the second category uses fluorescence probe attached to 
oligonucleotides such as TaqMan probe. This hydrolysis probe consists of reporter 
fluorophore at 5’ end and quencher at 3’ end, and it only detects specific amplicon 
(Figure 1.3).   
                                            
Figure 1.3 TaqMan probe (Arya et al., 2005) 
 
 9 
The selection of a specific DNA target template plays a key role in the specificity of 
qPCR testing method for porcine DNA detection. Mitochondria DNA (mtDNA) was 
commonly used for DNA target template in animal species identification (Zhang, 
2006; Man et al., 2010; Ali et al., 2012;). The advantage of mtDNA is that it is 
abundant in mitochondrion (Wiesner et al., 1992) compared to DNA which is 
contained in cell nucleus or nuclear DNA. Besides, there are in range of 1000 to 
2000 mitochondria that can be found in each cell (Radu et al., 2009). These will help 
in retrieval of DNA from highly processed products. MtDNA is highly evolved and 
diverse compared to nuclear DNA, thus DNA similarity between species that are 
closely related can be reduced (Wolf et al., 1999).  
 
PCR inhibitor can be defined as any foreign substance contained in extracted DNA 
sample that will disrupt PCR sensitivity by interfering with PCR analysis, leading to 
false negative results being obtained. The inhibitors are commonly found in food, 
processed product and environmental samples (Table 1.1). Besides, applying a poor 
DNA extraction and isolation technique and using contaminated reagent may also 
contribute to the presence of PCR inhibitor during PCR analysis. This problem can 
be countered by identifying the potential PCR inhibitor present in analysed sample, 
performing DNA extraction and isolation in a clean environment and washing out 
PCR inhibitor by optimizing DNA extraction and isolation method. 
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Table 1.1 List of common PCR inhibitors (Bessetti, 2007; Shrader et al., 2012) 
Inhibitor Source of Inhibitor 
Complex polysaccharides Plant material, stool 
Collagen Tissues 
Proteinases Milk 
Indigo dye Denim 
Surfactant Buffer 
Clay and its derivative Soil 
 
In commercial DNA detection kits, internal PCR control (IPC) or external DNA 
target control is used to identify the presence of PCR inhibitor during DNA 
amplification. This control is commonly made of synthetic oligonucleotide that has 
no similarity with target sequence and is amplified together with the DNA samples 
(Kontanis et al., 2006).  
 
1.5 TABLET AS A PHARMACEUTICAL DOSAGE FORM 
 
 Tablet is the most common type of pharmaceutical dosage form and is 
frequently found in the market especially as prescribed medicines and health 
supplement products. The advantages of using tablet as an oral dosage form are that 
it is a convenient form of drug administration, it can be produced in uniform dose 
from tablet to tablet on high-speed compression, and it is also stable in extended and 
diverse storage conditions (Lieberman et al., 1989; Aulton, 2007).  
 
There are various types of tablet formulations; they include compressed tablet, 
prolonged release tablet, coated tablet, disintegrating tablet, chewable tablet, 
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effervescent tablet and lozenges (Lieberman et al., 1990). The most common 
compressed tablet formulation is the uncoated tablet. Uncoated tablet can be 
produced by direct compressing, dry granulation and wet granulation. Direct 
compression is applied using tablet press instruments such as single-punch press, 
rotary press and computerized hydraulic press (Aulton, 2007). Dry and wet 
granulation methods are similar except dry granulation is favourable for active 
ingredient that is sensitive to heat and moisture.  
 
The formulation of uncoated tablet was further improved to coated tablet formulation 
especially to protect the drug from light and moisture. In coated tablet formulation, 
there are three main types that are commonly used in the pharmaceutical industry; 
film coating, sugar coating and compression coating (Porter, 1999).  In film coating, 
polymer is sprayed to cover the whole tablet surface and form a thin film. This form 
can be produced at high speed and therefore it is favourable compared to other 
coated tablet formulation. 
 
In recent years, modified release mechanism is desirable due to many advantages 
compared to immediate release mechanism. Modified release mechanism involves a 
continuous drug release in the body to sufficiently provide a prolonged duration of 
therapeutic action. The mechanism can be of benefit by reducing the drug dosage per 
day, which can lead to cost savings and less gastrointestinal side effects (Chien, 
1995).  There are various terms that fall under this modified release definition; they 
include delayed-release system, sustained-release system, extended-release system 
and controlled-release system. Sustained-release tablet formulation made up of a 
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hydrophilic matrix delivery system is less complexed to be produced at lab scale 
because the preparation method is similar to wet granulation method. 
 
 
1.5.1 Sources of non-halal excipients that are potentially found in tablets 
 
             A tablet consists of active ingredients and several excipients used to 
complete a tablet formulation and ease the tableting operation. An excipient is a 
processed product and can be categorized based on its function – diluent/filler, 
disintegrant, binder, lubricant and glidant. Diluent/filler is commonly used in tablet 
formulations when the amount of active ingredient is low and the filler is needed to 
be added to increase the tablet weight to at least 50 mg.  Lactose is the most common 
filler besides cellulose and sucrose because it is chemically inert, non-hygroscopic 
and has a tolerable taste. Disintegrant also plays an important role in tablet 
formulation. It promotes the tablet to disintegrate after consumption. Starch made 
from potato, maize and corn was the traditional disintegrant used in tablet 
formulation. Currently, modified starches such as pregelatinised starch and sodium 
starch glycolate are typically used and are effective disintegrants. A binder or 
adhesive is used to bind excipients mixture with drug during the granulation process. 
Gelatine and starch were the common traditional binders. Nowadays, polymers such 
as polyvinylpyrrolidone (PVP) and cellulose derivatives are used instead because of 
better adhesive properties.  Glidant is used to improve the flowability of granules 
during tableting press process. The most commonly used glidant is colloidal silica 
because the particle of silica is very small and can adhere to the other ingredient 
surfaces. During tablet press, lubricant act to reduce the friction between the granules 
and the die wall. The most effective lubricants are made from stearic acid and stearic 
acid salts. Magnesium stearate is widely used as a lubricant in tablet formulation. As 
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shown in Table 1.2, there is number of excipients that are derived from animal 
sources.  
 
Table 1.2 List of common excipients derived from animal sources (The Halal Index, 
2011) 
Excipients Sources Uses 
Gelatine Porcine & bovine Binder 
Magnesium stearate Porcine, bovine & plant Lubricant 
Stearic acid/ stearates Porcine, bovine & plant Lubricant 
Lactose monohydrate Porcine & bovine Filler 
Glycerine/ Glycerol Porcine, bovine & plant 
Humectant 
sweetening agent 
 
There is a potential that a tablet or its excipients may be adulterated or contaminated 
with haram sources such as gelatine from porcine source. Certain pharmaceutical 
companies did not declare the source origin of their excipients especially gelatine 
(Hussain, 2010). Most gelatine produced in United Kingdom (UK) was 80% made 
from porcine source because porcine is readily available compared to bovine gelatine 
(Boran et al., 2010). In 1986, UK reported 180,000 cases of Bovine Spongiform 
Encephalopathy (BSE) or widely known as mad cow disease, which is a 
neurodegenerative illness that can be deadly (Harman et al., 2009).  Due to the 
disease outbreak, pharmaceutical companies in the UK started to replace their 
gelatine source from bovine to porcine. Unfortunately, these changes posed a threat 
to Muslims and Jewish consumers as consumption of pork or any of its derivative is 
prohibited by the religious laws of Islam and Judaism (Ali et al., 2012).  
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1.6 PROBLEM STATEMENT AND OBJECTIVES OF STUDY 
 
 Awareness on halal pharmaceutical products have increased in recent years. 
This phenomenon is led by Muslim population that is widespread around the 
world and it also benefits other religion and belief systems such as Jewish and 
vegan communities. Currently, there is a need for analysis of porcine trace or 
adulteration in halal pharmaceutical products due to religious belief and also due 
to the use of undeclared animal species in halal products. In Malaysia Halal 
Pharmaceutical Standard (MS 2424:2012), there is no definite method to 
determine animal DNA contamination, specifically porcine DNA, in 
heterogeneous pharmaceutical products during tableting process and in excipients. 
Thus, a proper study on detecting porcine contamination at molecular level is 
essential to address this issue.  
 
During tableting process, porcine DNA shearing may occur. Also, porcine DNA 
may be entrapped by an excipient that has a high affinity to DNA. These factors 
will give an inaccurate result on porcine DNA detection. The aim of this study is 
to identify factors within tablet formulation and its processing that could hinder 
the detection of porcine DNA and subsequently develop a method that could 
circumvent these obstacles.      
 
    The objectives of this study encompass the following: 
 To formulate and prepare a template of adulterated tablet with porcine 
gelatine which conform to pharmaceutical standards. 
 To determine the crucial steps in tableting process that may affect 
porcine DNA recovery. 
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 To investigate the effect of excipient on porcine DNA detectability by 
qPCR testing method. 
 To develop an optimized DNA extraction and isolation method on 
tablet components that may hinder porcine DNA detection. 
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CHAPTER 2 :  PORCINE DNA DETECTION IN UNCOATED TABLETS                                                  
    AND THEIR EXCIPIENTS 
2.1 INTRODUCTION 
 
 Generally, tablets can be produced by dry or wet granulation methods 
depending on the active ingredient properties (Chaudari et al., 2012). In this study, 
wet granulation was chosen to produce uncoated tablets because this method is 
commonly used in pharmaceutical industry (Agrawal, 2011). Excipients were 
selected to suit wet granulation method, which contained filler, disintegrant, binder 
and lubricant as basic components in uncoated tablet formulation. In addition, 
gelatine was selected as a binder agent, the material from porcine source could be 
formulated as the positive control uncoated tablet. The selected excipients were 
chosen based on those commonly used in wet granulation for immediate release 
uncoated tablet and mostly from animal or plant-derived. 
 
The main step in uncoated tablet preparation are mixing, granulation, drying and 
compaction. The extra step in wet granulation that differs from dry granulation is the 
drying step. There is a possibility that DNA recovery will be affected during this 
step due to drying the wet granules at high temperature (Hupfer et al., 1998).  
 
The aims of this chapter comprise the following: 
 To determine which excipient(s) used in formulating uncoated tablet could 
hinder porcine DNA recovery.  
 To perform porcine DNA detection on a template of adulterated uncoated 
tablet with porcine gelatine.  
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 To investigate the effect of drying the tableting process on porcine DNA 
recovery.  
2.2 MATERIALS AND METHODS 
 
The excipients used were lactose monohydrate (DFE Pharma, Germany), 
microcrystalline cellulose (Avicel PH-102, Mingtai Chemical, Taiwan), sodium 
starch glycolate (Yung Zip Ltd, Taiwan), magnesium stearate (RMK Chemical, 
India), bovine gelatine bloom 180 (Leverage, Malaysia). Porcine gelatine bloom 180 
(Sigma-Aldrich, Germany) was used as a spike material.  
2.2.1   Selection of excipients for uncoated tablet formulation 
The sources of origin for all excipients were mostly from plant source. The 
excipients used in formulating immediate release uncoated tablets are listed in Table 
2.1.  
Table 2.1 Excipients used in the formulation of immediate release tablet 
Excipients Functional category Source 
Lactose monohydrate Filler/diluent Bovine 
Gelatine Binder Bovine & porcine 
Microcrystalline 
cellulose (MCC) 
Disintegrant Plant 
Sodium starch glycolate Disintegrant Plant 
Magnesium stearate Lubricant Plant & animal 
 
 
2.2.2   Porcine DNA detection on excipients used in the formulation of immediate 
 release uncoated tablets 
In this step, problematic excipient(s) that may hinder porcine DNA recovery was 
determined. Porcine DNA detection was carried out on unspiked and spiked 
excipients with porcine gelatine.  
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2.2.2(a) Sample preparation  
 
 The four selected excipients excluding gelatine (Table 2.1) used for 
formulating immediate release uncoated tablet were contained in two excipients 
groups. The first group of excipients was unspiked and the second group was spiked 
with porcine gelatine.  
 
Each excipient for group 1 was weighed approximately 100 mg and transferred into a 
labelled 1.5 ml sterile microcentrifuge tube. Excipient for Group 2 was weighed 
separately for 1 g and mixed with 1 ml of 8% w/v porcine gelatine solution in a clean 
mortar and pestle.  Then, 100 mg of wet mixture of Group 2 was weighed and 
transferred into a labelled 1.5 ml sterile microcentrifuge tube. All samples including 
porcine gelatine as internal positive control and bovine gelatine as negative control 
were prepared in duplicate for DNA extraction and isolation. The summary of 
sample preparation on excipients was shown in Figure 2.1. 
 
Figure 2.1 Flow chart of summary of sample preparation on excipients 
Sample 
preparation
0.1 ml of 8% w/v 
porcine and bovine 
gelatine solution
Group 1-unspiked
100 mg of each 
excipient was 
weighed
Transferred into 1.5 
ml sterile 
microcentrifuge 
tube
Group 2-spiked
1 g of each excipient 
was weighed
Mixed with 1 ml of 
8% w/v porcine 
gelatine
100 mg of wet 
mixture was weighed 
and transferred into 
1.5 ml sterile 
microcentrifuge tube
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2.2.2(b) DNA extraction and isolation 
 
 The procedure of DNA extraction and isolation for lactose monohydrate, 
MCC, gelatine and magnesium stearate was carried out as suggested in Agilent DNA 
Isolation kit (Agilent Technologies, USA) protocol, which contains nucleic acid 
binding buffer, high salt wash buffer, elution buffer, DNA-binding spin cups and 2 
ml receptacle tubes, 1.5 ml collection tubes, Proteinase K and Proteinase K digestion 
buffer. Sodium starch glycolate used different DNA extraction and isolation kit from 
other excipients, which is DNeasy Mericon Food kit (Qiagen, Germany) that 
contains Food Lysis buffer, Proteinase K, QIAquick® spin column, PB buffer, AW2 
buffer and EB buffer. DNA extraction and isolation on sodium starch glycolate was 
conducted according to DNeasy Mericon Food kit protocol. 
 
 
The DNA extraction and isolation started when 20 μl of Proteinase K and 200 μl of 
Proteinase K Digestion buffer were added and mixed into all samples tubes. Then, 
the tubes were incubated at 65°C with constant shaking at 800 rpm for 1 hour in a 
thermomixer (Thermomixer Comfort, Eppendorf, Germany).  
 
After 1 hour incubation, all tubes were centrifuged in a centrifuge (5424, Eppendorf, 
Germany) at 11,500 rpm for 6 minutes. Next, 150 μl of supernatant was collected 
from each tube and transferred into a new 1.5 ml sterile microcentrifuge tube 
containing 500 μl of nucleic acid binding buffer. The tube was vortexed using a 
vortex mixer (Vortex Genius 3, IKA, Germany) for 10 seconds to ensure a 
homogenous distribution mixture.  
 
Then, the mixture was transferred into DNA binding spin cup column placed in a 1.5 
ml collection tube. The collection tube was centrifuged at 14,680 rpm for 1 minute. 
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After centrifuged, the flow-through contaminant contained in the collection tube was 
discarded. Next, 500 μl of 1X high salt wash buffer was added into each DNA 
binding spin cup column and centrifuged at 11,100 rpm for 1 minute. The flow-
through contaminant contained in the collection tube after centrifuged was discarded 
and 500 μl of 80% v/v ethanol was added to wash away any salt residual on the 
column. Next, the collection tube was centrifuged at 11,100 rpm for 1 minute and the 
flow-through of the ethanol contained in the collection tube was discarded after 
centrifuged. This washing step of salt residual was repeated twice. Then, the 
collection tube was centrifuged again at 14,680 rpm for 2 minutes to dry the silica 
column membrane from ethanol residual.  
 
The DNA binding spin cup column was then placed in a new 1.5 ml collection tube 
and 100 μl of elution buffer taken that was being pre-heated from the thermomixer 
was added directly onto the DNA binding spin column membrane surface. After 
incubating DNA binding spin cup column at room temperature for 1 minute, the 
column was centrifuged at 14,680 rpm for 1 minute to elute the DNA adsorbed on 
DNA binding spin cup column membrane. Next, the DNA binding spin cup column 
was discarded. The eluted DNA collected in the collection tube was further tested for 
DNA purity and concentration.    
2.2.2(c) Assessment of DNA purity and concentration 
 
The quality and concentration of extracted DNA was determined using NanoVue 
Plus UV Vis spectrophotometer (GE Healthcare, UK). Elution buffer was used as a 
reference sample. A volume of 1 μl DNA sample from each excipient was placed 
onto the horizontal hydrophobic surface plate. The DNA concentration and purity of 
each excipient was measured and the results shown from spectrophotometer were 
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recorded. DNA concentration was calculated by multiplying OD260 reading with 50. 
DNA purity was determined by calculating the ratio of OD260 reading/OD280 reading. 
The DNA sample with purity value range of 1.8 to 2.0 was used for porcine DNA 
detection procedure.  
 
2.2.2(d) Porcine DNA detection 
 
 The amplification and detection of porcine DNA was performed using a 
commercial kit, Agilent Porcine Detection QPCR kit (Agilent Technologies, USA). 
All extracted DNA and controls, which are no-template control (NTC) and porcine 
DNA control supplied from the commercial kit, were prepared in triplicate. Porcine 
DNA control acts as a positive control in qPCR reaction. The porcine detection assay 
mix supplied from the kit, contains PCR primers, fluorogenic probe and external 
DNA control template or “Alien DNA”. PCR reagent mixture was prepared in a 1.5 
ml sterile microcentrifuge tube, which consists of 12.5 μl qPCR master mix and 2.5 
μl porcine detection assay mix. The final volume of PCR reagent mixture was 
prepared in a 1.5 ml sterile microcentrifuge tube. The volume for each components 
added in each reaction tube are as shown in Table 2.2.  
Table 2.2 Volume of components added in each reaction tube 
Reaction Tubes  
Components 
NTC Excipients Positive control 
PCR reagent mixture 15 μl 15 μl 15 μl 
Porcine DNA control - - 10 μl 
Nuclease-free water 10 μl - - 
DNA extract  - 10 μl - 
Final amount 25 μl 25 μl 25 μl 
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Subsequently, all reaction tubes were briefly spun in a mini centrifuge. The reaction 
tubes were placed in the thermal cycler, Mx3005P QPCR systems (Agilent 
Technologies, USA). Then, FAM and Cy5 channels were selected from the thermal 
cycler’s software. Next, the qPCR thermoprofile programme was run as shown in 
Table 2.3 and start to run the porcine DNA amplification. The starting point for 
fluorescence signal detection was during annealing and elongation stage. After the 
run had completed, the data analysis was recorded.  
Table 2.3 qPCR thermal profile programme 
PCR stage Number of 
Cycles 
Temperature (0C) Duration  
Initial 1 95 10 minutes 
Melting point 
40 
95 30 seconds 
Annealing & 
elongation 
60 
1 minute 
 
 
2.2.2(e)  DNA extraction and isolation of sodium starch glycolate using CTAB      
    method 
 
 DNA extraction and isolation began when 1 ml of Food Lysis buffer 
contained cetyltrimethylammonium bromide (CTAB) and 2.5 μl of Proteinase K 
were added and mixed into sample tubes. Then, the tube was incubated at 60°C with 
constant shaking at 1000 rpm for 30 minutes in a thermomixer. After the incubation, 
the tube was cool down for 15 minutes in a cold block. Then, the tube was 
centrifuged for 5 minutes at 5,150 rpm. After centrifugation, 700 μl of supernatant 
was withdrawn from each tube and transferred into a new 1.5 ml sterile 
microcentrifuge tube containing 500 μl of chloroform.  The tube was vortexed for 15 
seconds and centrifuged at 12,200 rpm for 15 minutes.  
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Next, 350 μl of supernatant from each tube was collected after centrifugation 
completed. The supernatant was transferred into a new 1.5 ml sterile microcentrifuge 
tube containing 350 μl of PB buffer. The tube was vortexed for 15 seconds to ensure 
a homogenous mixture. Then, the mixture was transferred into a QIAquick spin 
column placed in a 2 ml collection tube. The collection tube was centrifuged for 1 
minute at 13,800 rpm. After centrifugation, the flow-through solution in the 
collection tube was discarded. Next, 500 μl of AW2 buffer was added into the 
QIAquick spin column and recentrifuged at 13,800 rpm for 1 minute. The flow-
through solution contained in the collection tube was discarded and the spin column 
was recentrifuged again at 13,150 rpm for 1 minute to dry the membrane.  
 
The QIAquick spin column was transferred into a new 1.5 ml sterile microcentrifuge 
tube and 150 μl of EB buffer was added directly onto the QIAquick spin column 
membrane surface. After incubating the QIAquick spin column at room temperature 
for 1 minute, the column was centrifuged at 13,800 rpm for 1 minute to elute the 
DNA adsorb on QIAquick spin column membrane. Next, QIAquick spin column was 
discarded and the tube containing eluted DNA was further tested for DNA purity and 
concentration assessment as mentioned in section 2.2.2(c) and proceed with porcine 
DNA detection as mentioned in section 2.2.2(d).   
 
2.2.3   Preparation of uncoated tablets  
 
 In this study, a placebo uncoated tablet was formulated with selected 
excipients from those commonly used in wet granulation. The formulation for 
uncoated tablet was referred from a formulation that utilizes povidone (PVP) as a 
tablet binder. The original formulation was modified by replacing PVP to gelatine 
and suitable concentration of gelatine solution was identified. In order to optimise 
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the formulation, two concentrations of gelatine solutions were used in this 
formulation, which are 10% w/w and 8% w/w of gelatine solution. The formulations 
were prepared with excipients as listed in Table 2.4.  
Table 2.4 Formulations of uncoated tablet 
Excipients 
Formulations 
F1  F2  
Lactose monohydrate 392.0 401.8 
Gelatine  49.0 39.2 
MCC 14.7 14.7 
Sodium starch glycolate 29.4 29.4 
Magnesium stearate 4.9 4.9 
Total tablet weight (mg) 490 490 
 
First, 10% w/w of gelatine solution from bovine source was prepared by dissolving 
in distilled water at 45°C. All excipients were weighed and except magnesium 
stearate were transferred and mixed in a plastic bag for 5 minutes. Then, pre-blend 
was transferred into a planetary mixer (KM010 mixer, Kenwood, UK) and mixed at 
speed of 10 rpm for 2 minutes. Next, half volume of 10% w/w gelatine solution was 
added and mixed at speed of 40 rpm for 5 minutes. The end point of wet mixing was 
achieved when a smooth crack surface appeared by pinching the wet powder blend at 
90°. Later, the wet powder blend was granulated using granulator (YK 60B, China 
Pharmaceutical Machinery Factory, China) with sieve size 800 μm, followed by 
drying of the wet granules in fluidized bed dryer (TG 200, Retsch, Germany) for 8 
minutes at 65°C. Then, the dried granules were transferred into the planetary mixer 
and wet mixing was repeated using another half of gelatine solution. Next, the wet 
mixing was re-granuled using granulator and dried again using fluidized bed dryer 
for 8 minutes at 60°C. Finally, the dried granules were screened from dried powder 
blend using automated sieve (AR 401, Erweka, Germany) with sieve size 630 μm 
